Market Cap 124.87M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 401,200
Avg Vol 621,750
Day's Range N/A - N/A
Shares Out 30.68M
Stochastic %K 33%
Beta 0.55
Analysts Strong Sell
Price Target $13.00

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
Heroforest
Heroforest Oct. 26 at 2:44 AM
$VTGN if they don’t announce last patient visit next week I assume they will miss the q4 deadline? Anyone?
0 · Reply
josh77
josh77 Oct. 25 at 7:42 PM
$ICU Strategic Partnership Scenario Trigger: Collaboration with a major medtech or dialysis provider Catalyst: Licensing deal or co-commercialization agreement Impact: Validates technology Provides non-dilutive funding Expands distribution and hospital access Stock Price Potential: $2.X–$4.X range, depending on deal terms $WGRX $VTYX $VTGN $VKTX
0 · Reply
mb0157
mb0157 Oct. 25 at 2:32 PM
$VTGN Paying close attention next week to options action in this one. I still think swinging is going to shake out at CNS summit nov 2. The $5 nov calls have been firm. This has been Dr Monti’s favorite stage the past several years. Very hard for me to imagine they aren’t there. Still calling a licensing or partner deal here. Just my opinion.
0 · Reply
Haimalon
Haimalon Oct. 25 at 7:10 AM
0 · Reply
MakesHerSquirt
MakesHerSquirt Oct. 24 at 10:45 PM
$VTGN Buy the big dip B4 Positive phase 3. Come on brothers do you really think all these tutes would own so much. Let's make some money and do good with it.
0 · Reply
Ruzmadji
Ruzmadji Oct. 24 at 9:09 PM
$VTGN Monday can be the Day! LMAO
0 · Reply
Young_s
Young_s Oct. 24 at 5:52 PM
$VTGN https://clinicaltrials.gov/study/NCT06358651?spons=VistaGen%20Therapeutics,%20Inc.&rank=3&a=9&b=10&compareMode=sideBySide&tab=history October 24th PAL3 Report Update There is no change to the expected completion date for the last patient. It's still scheduled for October.
1 · Reply
BioBum
BioBum Oct. 24 at 5:31 PM
$VTGN feel like there’s always a dip before a successful readout. There’s absolutely no scientific basis about it, but you just have to have been in bio a long time to know what I’m saying. Where’s the dip?! are we topped out now?
1 · Reply
HelpMeImPoorr
HelpMeImPoorr Oct. 24 at 3:11 PM
$VTGN no PR?
0 · Reply
kimgysen
kimgysen Oct. 24 at 3:07 PM
$VTGN Holding 4 like a boss for now
0 · Reply
Latest News on VTGN
Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 3 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference


Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 8 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum


Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference


Heroforest
Heroforest Oct. 26 at 2:44 AM
$VTGN if they don’t announce last patient visit next week I assume they will miss the q4 deadline? Anyone?
0 · Reply
josh77
josh77 Oct. 25 at 7:42 PM
$ICU Strategic Partnership Scenario Trigger: Collaboration with a major medtech or dialysis provider Catalyst: Licensing deal or co-commercialization agreement Impact: Validates technology Provides non-dilutive funding Expands distribution and hospital access Stock Price Potential: $2.X–$4.X range, depending on deal terms $WGRX $VTYX $VTGN $VKTX
0 · Reply
mb0157
mb0157 Oct. 25 at 2:32 PM
$VTGN Paying close attention next week to options action in this one. I still think swinging is going to shake out at CNS summit nov 2. The $5 nov calls have been firm. This has been Dr Monti’s favorite stage the past several years. Very hard for me to imagine they aren’t there. Still calling a licensing or partner deal here. Just my opinion.
0 · Reply
Haimalon
Haimalon Oct. 25 at 7:10 AM
0 · Reply
MakesHerSquirt
MakesHerSquirt Oct. 24 at 10:45 PM
$VTGN Buy the big dip B4 Positive phase 3. Come on brothers do you really think all these tutes would own so much. Let's make some money and do good with it.
0 · Reply
Ruzmadji
Ruzmadji Oct. 24 at 9:09 PM
$VTGN Monday can be the Day! LMAO
0 · Reply
Young_s
Young_s Oct. 24 at 5:52 PM
$VTGN https://clinicaltrials.gov/study/NCT06358651?spons=VistaGen%20Therapeutics,%20Inc.&rank=3&a=9&b=10&compareMode=sideBySide&tab=history October 24th PAL3 Report Update There is no change to the expected completion date for the last patient. It's still scheduled for October.
1 · Reply
BioBum
BioBum Oct. 24 at 5:31 PM
$VTGN feel like there’s always a dip before a successful readout. There’s absolutely no scientific basis about it, but you just have to have been in bio a long time to know what I’m saying. Where’s the dip?! are we topped out now?
1 · Reply
HelpMeImPoorr
HelpMeImPoorr Oct. 24 at 3:11 PM
$VTGN no PR?
0 · Reply
kimgysen
kimgysen Oct. 24 at 3:07 PM
$VTGN Holding 4 like a boss for now
0 · Reply
Gabriel_DS
Gabriel_DS Oct. 24 at 1:04 PM
$VTGN they presented new data yesterday and no PR, very weird
0 · Reply
tomlin_ashcroft
tomlin_ashcroft Oct. 24 at 1:50 AM
$VTGN — are getting tricks or treats this Halloween?
0 · Reply
MoffaMan
MoffaMan Oct. 24 at 12:47 AM
$VTGN what happen with the big presentation? - I guess nothing
0 · Reply
StoinkMaestro
StoinkMaestro Oct. 23 at 11:08 PM
$VTGN extremely low volume this thing gonna blast off with good news from top line. Easy 5x conservatively
0 · Reply
a_rational_investor
a_rational_investor Oct. 23 at 10:25 PM
$VTGN 👀
0 · Reply
printcomm
printcomm Oct. 23 at 9:40 PM
$VTGN Poster Presentations: Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time Title: PH80 Nasal Spray: In Vitro Receptor Binding, Effects on Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans— A Potential, Novel, Rapid, Non-hormonal Treatment for Vasomotor Symptoms due to Menopause Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD Poster Number: P-124 Date: Thursday, October 23, 2025, 6:15 p.m. to 7:15 p.m. Eastern Time Title: PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Potential, Novel, Rapid, Non-hormonal, Treatment for Vasomotor Symptoms due to Menopause Authors: Louis Monti, MD, PhD; Ross A. Baker, PhD; Rita Hanover, PhD
2 · Reply
Gabriel_DS
Gabriel_DS Oct. 23 at 7:51 PM
$VTGN so no fomo for the PR after hours
0 · Reply
Sorted_Details
Sorted_Details Oct. 23 at 7:16 PM
$VTGN For the last month someone has been propping this up, occasionally stepping in at tactical moments to maintain momentum. Not sure why people have the idea that shorts are playing around here, the ratio is low and there no juice to squeeze. Prop started after CFO resignation announcement on 9/15 yet no 13 f/g disclosures for Sep. Makes me wonder...
1 · Reply
Dan1019
Dan1019 Oct. 23 at 5:35 PM
$VTGN Hope we'll get the good news over the weekend and ruin the shorts' day off 😆😆😆
1 · Reply
kimgysen
kimgysen Oct. 23 at 5:14 PM
$VTGN Just in case you are interested in becoming a body building monk too
0 · Reply
Bran0723
Bran0723 Oct. 23 at 2:25 PM
$VTGN 🚀⏳
0 · Reply
Strizzball
Strizzball Oct. 23 at 1:08 PM
$VTGN https://www.vistagen.com/news-releases/news-release-details/vistagen-present-menopause-society-2025-annual-meeting
0 · Reply